Development of a pan-corona vaccine against novel pandemic viruses | University of Helsinki

Vincenzo Cerullo is Professor of Biological Drug Development, HiLIFE fellow, and Head of Drug Research Program at the Faculty of Pharmacy of the University of Helsinki. Dr. Cerullo started the ImmunoViroTherapy Lab in 2012, after being awarded the tenure-track professorship at the University of Helsinki. In these years, IVTLab has raised more than 5 million Euros for research, including the prestigious ERC Consolidator Grant, HiLIFE fellow and Jane and Aatos Erkko Foundation grant, to research how viruses can be used as platforms to induce and/or orchestrate the tumor-specific immune response. The group has produced tens of scientific papers and patents, and has co-founded a multimillion spin-off company together with the University of Helsinki. During the COVID-19 pandemic, Dr. Cerullo has also been working on developing a prophylactic and therapeutic vaccine for SARS-COV-2.
In this talk, Dr, Cerullo presents PeptiVAC, a ”plug & play” technology to boost anti-COVID-19 vaccines that are already in clinic, and GlobeVAC, a novel made-in-Finland formulation to store and ship virus-based vaccines without the need of the cold chain.
This talk was part of the event "Fighting the pandemic - COVID-19 research at the University of Helsinki" organized by HiLIFE (www.helsinki.fi/en/helsinki-i....
Read more about the event:
www.helsinki.fi/en/news/healt...
More info about ImmunoViroTherapy Lab:
www.helsinki.fi/en/researchgr...
VALO therapeutics:
www.valotx.com/

[@zod6250]

Great work. The delivery package next.